A clinical trial is a research study involving human volunteers, and is designed to answer specific health questions. Carefully conducted clinical trials are the safest and fastest way to find effective treatments, and new ways to improve health.
You can search for all studies that are currently enrolling participants at the University of Rochester by typing in keywords in the search box below. If you don’t find a study that interests you right now, consider signing up for our Volunteer Registry, which will notify you of future studies.
Adapting CBT-I for Hazardous Alcohol Users
Lead Researcher: Wilfred Pigeon
The goal of this intervention development trial is to develop, refine, and test a
telephone-delivered, 4-session version of cognitive behavioral therapy for insomnia
adapted
to hazardous alcohol users with co-occurring insomnia. The project will begin with
a small,
open label pilot to refine the intervention and proceed to a small, randomized trial
comparing the intervention to a sleep and alcohol education control condition.
The two main questions it aims to answer are whether the intervention is feasible
to deliver
and whether its effects on alcohol use and insomnia severity are large enough to warrant
further work.
View Study Details
BEGIN - A Breastfeeding Study
Lead Researcher: Bridget Young
We are looking for:
- Mothers who are exclusively pumping for babies 1-2 months old
- Participation will last until your baby is 4 months old
- We will have you collect breastmilk, stool, urine, and saliva at home
- This study is totally remote – no need to ever leave your house!
Earn $100/month & receive breastfeeding support from our team!
View Study Details
CMMY19113 / S1803 / Brea Lipe
Lead Researcher: Brea Lipe
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to
Reg Step 2. Patients are followed until they will begin Maintenance and then registered
to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide
for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance,
MRD is assessed to guide further therapy. MRD-positive patients will continue with
the assigned treatment. MRD-negative patients will be further randomized (Reg Step
3) to either continue or discontinue the assigned treatment. Patients are treated
for up to 7 years from Step 2 reg and followed for up to 15 years.
View Study Details
Lung Health Cohort
Lead Researcher: Sandhya Khurana
Because lung function reaches its peak level between the ages of 25-35 years old,
we are beginning our study with people only in this age range. If you are in this
age range and have no history of chronic (i.e. long-lasting) lung diseases - other
than mild asthma - and no history of cardiovascular disease, you may be eligible to
join this study. This study involves a combination of in-person exams (during a single
visit), at-home tasks, and remote contact (via video conference, text message, email,
phone, or mail). During the in-person visit, we will test your lung function, take
images of your chest (CT scans), and ask you to provide biospecimen samples (blood,
urine, and nasal samples). There is an at-home portion to this study where you will
wear an activity monitor for one week, and you will perform breathing tests at home.
We will follow-up with you remotely every 3 to six months (up to 4 times per year)
until the end of the study.
View Study Details
RTOG 1216 / RHAN13055 / Surgery and Postoperative Radiation / Yuhchyau Chen
Lead Researcher: Yuhchyau Chen
This phase II/III trial studies how well radiation therapy works when given together
with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating
patients with high-risk stage III-IV head and neck cancer the begins in the thin,
flat cells (squamous cell). Specialized radiation therapy that delivers a high dose
of radiation directly to the tumor may kill more tumor cells and cause less damage
to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work
in different ways to stop the growth of tumor cells, either by killing the cells or
by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere
with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. The purpose
of this study is to compare the usual treatment (radiation therapy with cisplatin
chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy,
and using the usual treatment plus an immunotherapy drug, atezolizumab.
View Study Details
Study of Ecopipam Tablets for Tourette's Disorder in Children, Adolescents and Adults
Lead Researcher: Jennifer Vermilion
Tourette’s Disorder (TD) is a neurological disorder characterized by motor or vocal
tics that begin in childhood and persist over time. Motor tics can include such things
as eye-blinking, facial grimacing, mouth movements, head jerks, shoulder shrugs and
arm/leg jerks. Vocal tics
are fast meaningless sounds or noises, and include such things as sniffing, throat
clearing,
grunting, barks and squealing.
This study will determine if people with Tourette's Disorder who take Ecopipam for
8 weeks and see an improvement in tics, relapse when Ecopipam is slowly stopped.
There will be a control group that will receive placebo.
You may be eligible to join if you are 6 years of age or older, have a Tourette's
diagnosis and have motor and vocal tics that impair normal daily routines.
View Study Details